Literature DB >> 11992756

The ketogenic diet: a review of the experience at Connecticut Children's Medical Center.

Francis J DiMario1, Jessica Holland.   

Abstract

We undertook a retrospective analysis of epilepsy patients referred and treated for more than 6 months with the ketogenic diet during 1994-1999 at Connecticut Children's Medical Center. Outcome measures included antiepileptic drug number, seizure frequency, electroencephalogram background/paroxysmal activity, and adverse effects at 6 months and 1 year on the ketogenic diet. The final cohort included 24 of 48 referred patients (mean age, 6.5 years; range = 1-15 years of age). The etiology of epilepsy was equally divided between idiopathic and cryptogenic epilepsy and symptomatic epilepsy. Intention to treat analysis revealed that 35% (17 of 48) achieved more than 50% reduction in seizure frequency, and 8.5% (four of 48) were seizure-free by 6 months. A sustained 50% or greater reduction at 1 year was observed in 23% (11 of 48), and the same 8.5% (four of 48) remained seizure-free. None of these improvements were statistically related to age (P = 0.97), sex (P = 0.78), or epilepsy etiology (P = 0.80). The number of antiepileptic drugs used per patient decreased. Electroencephalogram at 1 year demonstrated an improvement in background in 31% (five of 16 patients) and a reduction in paroxysmal features in 37.5% (6 of 16 patients). Most adverse effects were mild, self-limited, and occurred early. Hyperuricemia (more than 6 mg/dL) was more persistent in three patients.

Entities:  

Mesh:

Year:  2002        PMID: 11992756     DOI: 10.1016/s0887-8994(01)00405-2

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  10 in total

1.  Renal stone associated with the ketogenic diet in a 5-year old girl with intractable epilepsy.

Authors:  Ji Na Choi; Ji Eun Song; Jae Il Shin; Heung Dong Kim; Myung Joon Kim; Jae Seung Lee
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

Review 2.  Epigenetics and epilepsy prevention: The therapeutic potential of adenosine and metabolic therapies.

Authors:  Detlev Boison; Jong M Rho
Journal:  Neuropharmacology       Date:  2019-08-13       Impact factor: 5.250

3.  Methionine and choline regulate the metabolic phenotype of a ketogenic diet.

Authors:  Pavlos Pissios; Shangyu Hong; Adam Richard Kennedy; Deepthi Prasad; Fen-Fen Liu; Eleftheria Maratos-Flier
Journal:  Mol Metab       Date:  2013-07-08       Impact factor: 7.422

4.  Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity.

Authors:  S A Masino; M Kawamura; C D Wasser; C A Wasser; L T Pomeroy; D N Ruskin
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 5.  Ketogenic diet, neuroprotection, and antiepileptogenesis.

Authors:  Madhuvika Murugan; Detlev Boison
Journal:  Epilepsy Res       Date:  2020-08-19       Impact factor: 3.045

6.  Ketogenic diets for drug-resistant epilepsy.

Authors:  Kirsty J Martin-McGill; Cerian F Jackson; Rebecca Bresnahan; Robert G Levy; Paul N Cooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-07

7.  Ketogenic diets for drug-resistant epilepsy.

Authors:  Kirsty J Martin-McGill; Rebecca Bresnahan; Robert G Levy; Paul N Cooper
Journal:  Cochrane Database Syst Rev       Date:  2020-06-24

8.  Protein-Losing Enteropathy as a Complication of the Ketogenic Diet.

Authors:  Won Kee Ahn; Soyoung Park; Heung Dong Kim
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

9.  Implementation of ketogenic diet in children with drug-resistant epilepsy in a medium resources setting: Egyptian experience.

Authors:  Mary Gerges; Laila Selim; Marian Girgis; Amr El Ghannam; Hadeer Abdelghaffar; Ahmed El-Ayadi
Journal:  Epilepsy Behav Case Rep       Date:  2018-11-23

Review 10.  Ketogenic diet in the treatment of cancer - Where do we stand?

Authors:  Daniela D Weber; Sepideh Aminzadeh-Gohari; Julia Tulipan; Luca Catalano; René G Feichtinger; Barbara Kofler
Journal:  Mol Metab       Date:  2019-07-27       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.